Chicago CCFC for the new AsA-NHPI cohort - ODS Admin Supplement - ABSTRACT Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in the United States, yet the biological impact of widely used orally ingested botanical supplements remains insufficiently characterized in population-based studies. This knowledge gap is especially pronounced among Asian American communities, where culturally patterned supplement use is common but rarely evaluated within deeply phenotyped cardiovascular cohorts. Turmeric (Curcuma longa) and its bioactive constituent curcumin, and ginseng (Panax spp.), are among the most frequently consumed botanical supplements in Korean, Indian, and Filipino populations for perceived benefits related to cardiovascular health, inflammation, metabolic balance, energy, and resilience. Experimental studies suggest that curcumin and ginsenosides influence inflammatory, oxidative stress, endothelial, and metabolic pathways relevant to cardiovascular disease prevention; however, few studies have linked habitual supplement use to objective circulating metabolites and cardiometabolic biomarkers in real- world populations. This 1-year pilot study will leverage the Chicago Clinical/Community Field Center of the NHLBI Multi-ethnic Observational Study of American Asian and Pacific Islander Communities (MOSAAIC) to investigate oral turmeric/curcumin and ginseng use among Korean, Indian, and Filipino adults. Approximately 150 participants will complete a targeted supplement assessment capturing frequency, duration, formulation, dose, and culturally specific use patterns. Reported products will be harmonized using NIH Office of Dietary Supplements (ODS) resources, including DSID, DSLD, and CARDS. Baseline plasma specimens will be analyzed using targeted liquid chromatography-mass spectrometry methods to quantify circulating curcumin metabolites and selected ginsenosides. These objective exposure markers will be evaluated in relation to inflammatory biomarkers (IL-6, TNF-α, MCP-1), myocardial stress markers (NT-proBNP, troponin), metabolic biomarkers (resistin, leptin, C-peptide, ghrelin), and clinical metrics including blood pressure, body mass index, and Life’s Essential 8 score. This pilot will generate preliminary metabolite-integrated evidence linking oral botanical supplement use with cardiometabolic biology in historically understudied populations. Findings will provide critical preliminary data for larger ODS-aligned studies and establish a scalable framework for integrating supplement science into national cardiovascular cohorts.
